Harmine

Pricing Availability   Qty
说明: Potent and selective DYRK1A inhibitor
化学名: 7-Methoxy-1-methyl-9H-pyrido[3,4-b]indole
纯度: ≥98% (HPLC)
说明书
引用文献 (2)
评论
文献 (2)

生物活性 for Harmine

Harmine is a potent and selective inhibitor of DYRK1A (IC50 values are 80, 800 and 900 nM for DYRK1A, DYRK3 and DYRK2 respectively). Inhibits DYRK1A-mediated tau phosphorylation and regulates PPARγ expression. Harmine also induces pancreatic β cell proliferation and exhibits antidiabetic activity. Orally bioavailable. Harmine has high affinity (Kd = 100 nM) for the yjdF aptamer. The riboswitch function of yjdF motif RNAs is activated by Harmine and leads to robust reporter gene expressions in B. subtilis.

技术数据 for Harmine

分子量 212.25
公式 C13H12N2O
储存 Store at RT
纯度 ≥98% (HPLC)
CAS Number 442-51-3
PubChem ID 5280953
InChI Key BXNJHAXVSOCGBA-UHFFFAOYSA-N
Smiles CC1=NC=CC2=C1NC3=C2C=CC(OC)=C3

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for Harmine

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 21.23 100
ethanol 1.06 5 温和加热

制备储备液 for Harmine

以下数据基于产品分子量 212.25。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 4.71 mL 23.56 mL 47.11 mL
5 mM 0.94 mL 4.71 mL 9.42 mL
10 mM 0.47 mL 2.36 mL 4.71 mL
50 mM 0.09 mL 0.47 mL 0.94 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for Harmine

分析证书/产品说明书
选择另一批次:

按产品操作查看相关产品

查看全部 DYRK Inhibitors

关键词: Harmine, Harmine supplier, Harmine, dyrk1a, dyrk, inhibitors, inhibits, potent, selective, dual, specificity, tyrosine, phosphorylation, regulated, kinase-1A, PPARg, PPARgamma, PPARγ, antidiabetic, high, affinity, to, yjdF, aptamer, RNA, activates, riboswitch, Microtubules, DYRK, DNA,, and, Protein, Synthesis, 5075, Tocris Bioscience

2 篇 Harmine 的引用文献

引用文献是使用了 Tocris 产品的出版物。 Harmine 的部分引用包括:

Sourav et al (2021) The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress. Cell Death Differ 28 1563-1578 PMID: 33268814

Singh et al (2017) Different developmental histories of beta-cells generate functional and proliferative heterogeneity during islet growth. Nat Commun 8 664 PMID: 28939870


您是否知道使用了 Tocris Harmine 的优秀论文? 请告知我们.

Harmine 的评论

目前没有该产品的评论。 Be the first to review Harmine and earn rewards!

Have you used Harmine?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.